Biotechnology Scientific Misconduct Regulation In Russia.
1. Introduction
Biotechnology Scientific Misconduct Regulation in Russia concerns the legal, institutional, scientific and ethical mechanisms used to prevent, investigate and punish misconduct in biotechnology research and development.
Scientific misconduct occurs when researchers, biotechnology companies, laboratories, universities or research institutions deliberately manipulate scientific evidence, falsify experimental results, plagiarise research, conceal adverse findings or violate research ethics.
In biotechnology, misconduct is particularly serious because scientific findings may directly affect:
Human health and clinical treatment.
Genetic engineering and genome-editing research.
Stem-cell and embryo research.
Vaccine and pharmaceutical development.
Genetically modified organisms (GMOs).
Biological safety and pathogen research.
Reproductive biotechnology.
Scientific publications and patent applications.
Russia does not have one comprehensive federal statute exclusively dedicated to scientific misconduct. Instead, misconduct is addressed through a combination of federal legislation, government regulations, institutional disciplinary procedures, research ethics requirements, civil liability and criminal law.
The central legal framework includes Federal Law No. 127-FZ of 23 August 1996 on Science and State Scientific and Technical Policy, Federal Law No. 273-FZ on Education, Federal Law No. 61-FZ on Circulation of Medicines and applicable provisions of the Russian Criminal Code.
rostransnadzor.gov.ru+2
2. Meaning and forms of scientific misconduct
Scientific misconduct in Russian biotechnology research can take several forms.
A. Research fabrication
Fabrication occurs when a scientist invents experimental results, laboratory observations, clinical outcomes or biological evidence that was never obtained.
Examples include:
Inventing genetic sequencing results.
Creating false vaccine efficacy statistics.
Reporting experiments that were never conducted.
Fabricating animal-testing results.
Inventing clinical-trial participants or patient records.
In biotechnology, fabricated evidence can result in unsafe products reaching clinical development or commercial markets.
B. Research falsification
Falsification involves deliberately manipulating genuine research material, equipment, experimental procedures or scientific data.
Examples include:
Manipulating DNA sequencing results.
Altering gene-expression measurements.
Removing unsuccessful experimental observations.
Manipulating microscopy images.
Concealing adverse effects in clinical research.
The distinction is important: fabrication involves inventing evidence, whereas falsification involves improperly manipulating existing evidence.
C. Plagiarism
Plagiarism involves using another researcher's scientific work, text, discoveries or results without appropriate attribution.
Examples include copying:
Biotechnology research papers.
Genetic engineering discoveries.
Scientific methodologies.
Dissertation chapters.
Experimental datasets.
Plagiarism may also raise copyright infringement issues under Part IV of the Russian Civil Code.
D. Authorship manipulation
Scientific misconduct may also involve:
Gift authorship.
Ghost authorship.
Removing genuine contributors.
Falsely claiming scientific discoveries.
Selling authorship positions in scientific publications.
These practices undermine the reliability of scientific publications and research accountability.
E. Concealment of adverse research findings
In biotechnology, researchers may deliberately conceal negative experimental outcomes, toxicological findings, failed clinical trials or unexpected genetic effects.
Such concealment becomes especially serious when it compromises patient safety, regulatory approval or public-health protection.
3. Main legislative framework governing scientific misconduct in Russia
A. Federal Law No. 127-FZ of 1996 – Science and State Scientific and Technical Policy
The most important general legislation is Federal Law No. 127-FZ, On Science and State Scientific and Technical Policy.
It establishes the legal framework for scientific research, scientific institutions, researchers and scientific results.
Its relevance to scientific misconduct includes:
Researcher responsibilities: Article 3 establishes the legal position of individuals and organisations conducting scientific and technological activities.
Protection of scientific integrity: Researchers must respect the applicable legal requirements governing scientific activities.
Research safety: Scientific activity must respect human rights, health and environmental protection requirements.
Scientific evaluation: The legislation establishes the framework for state scientific attestation and the awarding of academic degrees.
Institutional responsibility: Scientific organisations operate within the applicable statutory and regulatory framework.
An important limitation is that the law does not create a comprehensive standalone offence called scientific misconduct. Specific misconduct must be addressed under the relevant education, research, intellectual-property, medical or criminal-law provisions.
rostransnadzor.gov.ru+1
B. Federal Law No. 273-FZ of 29 December 2012 – Education in the Russian Federation
This legislation is important when scientific misconduct occurs in universities, postgraduate programmes and academic institutions.
It provides the general framework for:
Academic standards.
Educational institutional governance.
Student and postgraduate responsibilities.
Internal institutional regulations.
Academic assessment and disciplinary procedures.
For biotechnology students and doctoral researchers, plagiarism, falsification of dissertations and dishonest academic practices may result in institutional disciplinary measures.
A researcher who submits fabricated experimental data as part of a doctoral dissertation may also face consequences under the academic-degree regulations.
C. Government Resolution No. 842 of 24 September 2013
Important enforcement mechanism
The Government Resolution No. 842, On the Procedure for Awarding Academic Degrees, is particularly important in combating dissertation-related scientific misconduct.
It provides a mechanism for withdrawing academic degrees where statutory academic requirements have been violated.
Under its provisions, misconduct can include:
Plagiarism in dissertations.
Unauthorised use of scientific materials.
Fabricated research data.
Falsified scientific results.
False information concerning published scientific work.
Violations of dissertation submission and defence requirements.
The consequences may include cancellation of the decision awarding a degree and withdrawal of an already awarded academic qualification.
The procedure also provides for applications seeking withdrawal of academic degrees, supported by documentary evidence.
Under the applicable procedure, the Ministry of Science and Higher Education makes the final decision in the relevant cases.
ГАРАНТ+2
D. Federal Law No. 61-FZ of 12 April 2010 – Circulation of Medicines
This legislation becomes relevant when scientific misconduct affects pharmaceutical and biotechnology products.
For example, a biotechnology company developing a gene therapy or biological medicine may commit regulatory violations if it submits false research information during product registration.
Relevant concerns include:
Reliability of preclinical research.
Accuracy of clinical-trial documentation.
Manufacturing quality.
Safety and efficacy evidence.
Scientific documentation submitted to regulatory authorities.
False experimental evidence can undermine the reliability of regulatory approval and may expose responsible individuals or organisations to administrative, civil or criminal consequences under applicable legislation.
E. Federal Law No. 323-FZ of 21 November 2011 – Protection of Citizens' Health
This law is relevant where misconduct affects patients or human participants in biomedical research.
It provides the general legal framework for healthcare, medical intervention and protection of citizens' rights.
Its importance includes:
Informed consent.
Protection of patient rights.
Medical confidentiality.
Safety of medical interventions.
Responsibility for violations in healthcare activities.
For example, concealing serious adverse effects during a biotechnology clinical trial may create legal liability if it results in violations of patient-protection requirements.
F. Good Clinical Practice (GCP)
Russia has adopted clinical research requirements through its regulatory framework, including:
Ministry of Health Order No. 266 of 19 June 2003, concerning clinical practice rules.
GOST R 52379-2005, the national Good Clinical Practice standard.
Ministry of Health Order No. 200n of 1 April 2016, approving Good Clinical Practice rules.
These requirements are particularly significant for biotechnology clinical trials.
They address research documentation, informed consent, investigator responsibilities, trial monitoring and the reliability of clinical evidence.
A deliberate alteration of clinical-trial records can therefore become a serious regulatory matter.
static-0.minzdrav.gov.ru+1
4. Scientific misconduct in biotechnology: special regulatory concerns
Biotechnology creates scientific-integrity challenges that do not always arise in conventional academic research.
A. Genetic engineering and CRISPR research
Harnessing CRISPR: A Comprehensive Guide for Future Physi...
Super-precise CRISPR tool enters US clinical trials for the first time
First Patient Treated with On-Demand CRISPR in Just 6 Months
9
Scientific misconduct in genetic engineering can involve:
Falsifying genome-editing outcomes.
Concealing unintended genetic modifications.
Manipulating gene-expression data.
Falsifying laboratory safety records.
Misrepresenting the effectiveness of gene therapies.
For example, a research team might report that a CRISPR experiment successfully corrected a genetic mutation when the underlying experimental results do not support that conclusion.
Such conduct can undermine scientific publications, patent applications and clinical-development decisions.
B. Stem-cell and embryo research
China publishes world's first stem cell related intl standard_我苏网
Эмбриолог - врач эмбриолог, консультация, прием, запись
Reproductive specialist examining embryos through laboratory microscope
7
Potential misconduct includes:
Fabricating stem-cell experimental results.
Falsifying embryo-development observations.
Misrepresenting cell-line origins.
Using biological materials without required authorisation.
Concealing ethical approval deficiencies.
Where human participants, embryos or reproductive materials are involved, additional medical, reproductive and ethical requirements become relevant.
C. Vaccine and pharmaceutical biotechnology
New data show vaccines reduce severe COVID-19 in older adults | University of Oxford
Examples of misconduct include:
Fabricating vaccine efficacy results.
Concealing adverse reactions.
Manipulating clinical-trial datasets.
Falsifying manufacturing-quality records.
Misrepresenting biological product stability.
These activities can affect regulatory approval, patient safety and public confidence in biotechnology.
D. Genetic data and scientific publications
Scientific misconduct can also involve the misuse or manipulation of genetic databases.
Examples include:
Falsifying DNA sequencing datasets.
Misrepresenting population-genetics findings.
Publishing another researcher's genomic data without proper attribution.
Concealing errors in published research.
Misrepresenting the provenance of biological samples.
Depending on the facts, these matters can also engage Russian personal-data legislation, intellectual-property law and contractual obligations.
5. Institutional mechanisms for investigating scientific misconduct
Russian universities and scientific research institutions may investigate misconduct through institutional governance and ethics procedures.
The principal mechanisms include:
1. Institutional ethics committees
They examine ethical compliance in research involving humans, animals, biological materials and medical technologies.
2. Research integrity investigations
Institutions may investigate allegations of fabrication, falsification, plagiarism and improper authorship.
3. Scientific peer review
Independent experts may examine experimental methods, datasets, scientific conclusions and publication records.
4. Dissertation committees
Dissertation committees assess academic integrity and can participate in the procedures for cancelling an improperly awarded degree.
5. Ministry of Science and Higher Education
The Ministry has responsibilities under the state academic-attestation framework, including decisions concerning withdrawal of academic degrees.
6. Healthcare regulatory authorities
Where misconduct involves medicines or clinical research, the relevant healthcare authorities may investigate regulatory violations.
Importantly, an ethics committee's finding is not automatically a criminal conviction. Criminal responsibility requires the relevant legal elements to be established through the appropriate legal process.
6. Criminal and civil liability for biotechnology scientific misconduct
Russian law does not impose one universal criminal penalty for every form of research misconduct. The applicable offence depends on the conduct and its consequences.
| Legal provision | Possible relevance |
|---|---|
| Criminal Code Article 146 | Copyright infringement and plagiarism-related conduct where its statutory elements are met |
| Article 159 | Fraud involving dishonest acquisition of property or rights |
| Article 238 | Provision of goods or services that fail to meet applicable safety requirements |
| Article 292 | Official forgery by qualifying officials |
| Article 327 | Forgery or use of forged documents |
| Civil Code Part IV | Copyright and intellectual-property protection |
These provisions should not be interpreted as automatically criminalising every inaccurate scientific publication.
For example, an honest experimental mistake is not necessarily fraud or falsification. Criminal liability requires proof of the relevant offence, including any required intent, harm and other statutory elements.
Civil liability
A biotechnology institution may face civil claims where misconduct causes legally recognised damage.
Possible claims include:
Compensation for financial losses.
Compensation for harm to health.
Intellectual-property infringement claims.
Contractual damages.
Recovery of improperly obtained payments where legally justified.
Employment and disciplinary liability
Researchers may also face:
Formal reprimands.
Employment-related disciplinary measures.
Dismissal where legally justified.
Withdrawal of research responsibilities.
Revocation of academic degrees under the applicable procedure.
Retraction or correction of scientific publications.
7. Important Russian case law relating to scientific misconduct
A significant legal distinction must be made: Russian reported judicial decisions specifically concerning misconduct in biotechnology are limited. However, Russian academic-degree litigation provides relevant legal principles for biotechnology researchers, particularly where fabricated research, plagiarism or false scientific publications are involved.
The following decisions and legal materials are relevant.
Case 1. Russian Supreme Court – Decision No. АКПИ25-945, 11 February 2026
Recent judicial authority
Subject: Withdrawal of academic degrees and procedural requirements.
This decision concerns the legal framework governing applications for withdrawal of academic degrees under the Russian academic-attestation regulations.
The relevant provisions address allegations involving:
False or forged documents.
Inaccurate information about published scientific works.
Violations of dissertation requirements.
Unauthorised use of scientific materials.
Plagiarism in dissertations.
The procedure requires supporting documentary evidence. For plagiarism allegations, this can include the disputed dissertation passages and the original publications from which the material was allegedly taken.
Relevance to biotechnology:
Suppose a biotechnology researcher obtains a doctoral degree using fabricated genetic-engineering experiments or plagiarised molecular-biology research.
The relevant academic-attestation procedure can provide a basis for seeking withdrawal of the degree, provided the regulatory grounds and evidentiary requirements are satisfied.
The decision is important because it illustrates the legal significance of evidence and procedural requirements in academic-misconduct proceedings.
ГАРАНТ+1
Case 2. Russian academic-degree withdrawal proceedings under Government Resolution No. 842
Subject: Plagiarism and falsification of dissertation research.
Government Resolution No. 842 of 24 September 2013 establishes the procedure for awarding and withdrawing academic degrees.
The regulations recognise circumstances in which a degree may be withdrawn because the dissertation fails to satisfy the prescribed academic requirements.
These include plagiarism, fabricated research data and false information about published scientific work.
Biotechnology application:
Consider a hypothetical researcher who submits a doctoral dissertation claiming to have discovered a new gene-editing technique.
An investigation subsequently establishes that:
The experimental results were fabricated.
The researcher copied another scientist's findings.
The published articles did not contain the claimed research results.
These circumstances may justify proceedings for withdrawal of the academic degree.
This is a regulatory enforcement framework rather than a separate reported biotechnology court judgment.
ГАРАНТ+1
Case 3. Higher School of Economics – Academic Degree Withdrawal Regulations
Subject: Academic integrity, plagiarism and forged research results.
The Higher School of Economics has published institutional regulations addressing the withdrawal of academic degrees.
Under its published 2023 regulations, grounds include:
Borrowed materials or scientific results used without appropriate references where authorship is called into question.
Forged research data and results.
False information about published academic papers containing the principal dissertation findings.
The regulations also provide for submission of documented requests seeking withdrawal of academic degrees.
Biotechnology application:
These provisions are relevant to biotechnology dissertations involving molecular biology, pharmaceutical research, genetics and biomedical engineering.
For example, a researcher who uses another scientist's experimental results without attribution may face an academic-integrity investigation.
Legal qualification: These are institutional regulations, not a judgment of the Russian Supreme Court or a universal statutory rule applicable to every Russian university.
HSE University+1
Case 4. Dissernet research-misconduct investigations in Russia
Subject: Detection of plagiarism and falsification in scientific dissertations and publications.
Dissernet is a public research initiative established in 2013 that investigates suspected academic misconduct in Russian dissertations and scientific publications.
Its investigations have focused on:
Plagiarised dissertations.
Duplicate scientific publications.
Improper authorship.
Falsified academic research.
Questionable scientific journal practices.
Its research reported extensive suspected misconduct in dissertations and scientific publications.
Biotechnology relevance:
The same investigative methods can be applied to biotechnology publications by comparing original scientific datasets, experimental descriptions, images, genetic research results and publication histories.
However, Dissernet findings are not judicial determinations. Allegations must be independently assessed by the competent institution or authority.
PUBMET2019
8. Evidentiary requirements in scientific misconduct investigations
Scientific misconduct investigations require reliable evidence.
In biotechnology, the following evidence may be particularly important:
| Evidence | Legal significance |
|---|---|
| Original laboratory notebooks | Establishes the history of experiments |
| DNA sequencing records | Helps verify genetic research results |
| Clinical-trial records | Identifies inconsistencies in clinical evidence |
| Microscopy images | Helps investigate image manipulation |
| Laboratory equipment records | Assists in verifying experimental procedures |
| Research databases | Helps identify fabricated or altered datasets |
| Scientific publications | Supports plagiarism and authorship investigations |
| Ethics committee approvals | Establishes compliance with research ethics requirements |
| Research funding records | Helps investigate financial irregularities |
A proper investigation should distinguish between deliberate falsification and innocent scientific error.
For example, an unexpected CRISPR experimental result does not automatically establish misconduct. Evidence of intentional manipulation or another legally relevant violation is required.
9. International cooperation and biotechnology research integrity
Russian biotechnology research may involve international universities, pharmaceutical companies, research laboratories and scientific publishers.
Cross-border research creates additional legal challenges.
These include:
A. International research collaborations
Where researchers in Russia and another country collaborate, differences in research-integrity rules can complicate investigations.
B. Scientific publication disputes
A scientific article published internationally may be investigated by the journal, the research institution and other competent bodies.
C. Cross-border clinical trials
Clinical research involving multiple jurisdictions may require coordination of documentation, ethical review and regulatory responsibilities.
D. Biological sample integrity
The unauthorised alteration, misrepresentation or concealment of the origin of biological samples may create additional legal and ethical issues.
E. Research funding fraud
Falsified research results used to obtain international grants or commercial funding may raise contractual, civil and potentially criminal questions.
Russia's Federal Law No. 127-FZ also provides the broader legal framework for international aspects of scientific and technological activity.
rostransnadzor.gov.ru+1
10. Major challenges in Russian biotechnology scientific misconduct regulation
Several challenges deserve particular attention.
1. Absence of a single comprehensive misconduct statute: Scientific misconduct is addressed through multiple legal and institutional mechanisms.
2. Detection of sophisticated data manipulation: Advanced genomic and computational research makes independent verification difficult.
3. Institutional conflicts of interest: Research institutions may have financial or reputational interests in the results of investigations.
4. Authorship disputes: Biotechnology research often involves interdisciplinary teams, creating difficulties in determining individual scientific contributions.
5. Clinical-trial transparency: Incomplete or manipulated clinical documentation can undermine the reliability of medical evidence.
6. Retraction procedures: Correcting or retracting unreliable scientific publications is important, but publication retraction and legal liability are separate processes.
7. Protection of whistleblowers: Researchers who report misconduct may face professional or institutional difficulties.
8. Distinguishing error from fraud: Scientific uncertainty must not automatically be treated as deliberate misconduct.
11. Suggested compliance framework for Russian biotechnology institutions
A biotechnology institution seeking to prevent scientific misconduct should establish the following safeguards:
| Compliance measure | Purpose |
|---|---|
| Research integrity policy | Establishes standards of scientific conduct |
| Independent ethics committee | Reviews ethical research concerns |
| Laboratory data preservation | Prevents unauthorised alteration of evidence |
| Authorship declaration | Identifies genuine research contributions |
| Clinical-trial monitoring | Protects participants and research reliability |
| Independent statistical review | Identifies suspicious research findings |
| Whistleblower reporting system | Encourages reporting of misconduct |
| Research audit procedures | Identifies irregularities |
| Publication correction policy | Corrects unreliable scientific findings |
| Staff training | Promotes responsible scientific practices |
These measures should be incorporated into institutional policies, employment procedures, research contracts and applicable regulatory compliance programmes.
12. Conclusion
Biotechnology Scientific Misconduct Regulation in Russia operates through a combination of scientific legislation, academic-attestation regulations, healthcare requirements, research ethics procedures and general civil and criminal law.
Federal Law No. 127-FZ provides the general foundation for scientific activity, while Government Resolution No. 842 provides an important mechanism for addressing plagiarism and falsification in dissertations through academic-degree withdrawal procedures.
The Russian Supreme Court's Decision No. АКПИ25-945 of 11 February 2026 is particularly relevant to understanding the procedural and evidentiary requirements governing academic-degree withdrawal.
For biotechnology, the consequences of scientific misconduct extend beyond academic reputation. Fabricated genetic research, manipulated clinical-trial results and falsified pharmaceutical evidence can threaten human health, scientific reliability and public confidence in medical innovation.
The central legal principle is that scientific freedom does not protect deliberate scientific deception. Researchers and biotechnology institutions must comply with applicable legal requirements, maintain reliable research records and ensure that scientific findings are supported by authentic and verifiable evidence.
13. Important legislation and references
| Authority | Subject |
|---|---|
| Federal Law No. 127-FZ (1996) | Science and scientific policy |
| Federal Law No. 273-FZ (2012) | Education and academic institutions |
| Government Resolution No. 842 (2013) | Academic degrees and withdrawal |
| Federal Law No. 61-FZ (2010) | Circulation of medicines |
| Federal Law No. 323-FZ (2011) | Protection of citizens' health |
| Criminal Code of Russia | Fraud, forgery and other applicable offences |
| Civil Code of Russia, Part IV | Intellectual-property protection |
| GOST R 52379-2005 | Good Clinical Practice |
| Ministry of Health Order No. 200n (2016) | Good Clinical Practice rules |
Useful primary and research sources:
Federal Law No. 127-FZ – Science and State Scientific and Technical Policy.
Government Resolution No. 842 – Awarding Academic Degrees.
Russian Supreme Court Decision No. АКПИ25-945 (2026).
HSE Regulations for Awarding Academic Degrees.
Research Misconduct in Dissertations and Scientific Publications in Russia.
Research note: This is an academic legal overview, not a claim that every listed provision creates a standalone scientific-misconduct offence. The cited academic-degree and institutional materials should be distinguished from biotechnology-specific judicial precedents.

comments